Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Eur J Pharmacol ; 886: 173548, 2020 Nov 05.
Article in English | MEDLINE | ID: mdl-32926918

ABSTRACT

The global pandemic COVID-19, caused by novel coronavirus SARS-CoV-2, has emerged as severe public health issue crippling world health care systems. Substantial knowledge has been generated about the pathophysiology of the disease and possible treatment modalities in a relatively short span of time. As of August 19, 2020, there is no approved drug for the treatment of COVID-19. More than 600 clinical trials for potential therapeutics are underway and the results are expected soon. Based on early experience, different treatment such as anti-viral drugs (remdesivir, favipiravir, lopinavir/ritonavir), corticosteroids (methylprednisolone, dexamethasone) or convalescent plasma therapy are recommended in addition to supportive care and symptomatic therapy. There are several treatments currently being investigated to address the pathological conditions associated with COVID-19. This review provides currently available information and insight into pathophysiology of the disease, potential targets, and relevant clinical trials for COVID-19.


Subject(s)
Coronavirus Infections/complications , Coronavirus Infections/drug therapy , Molecular Targeted Therapy/methods , Pneumonia, Viral/complications , Pneumonia, Viral/drug therapy , COVID-19 , Clinical Trials as Topic , Humans , Pandemics
SELECTION OF CITATIONS
SEARCH DETAIL
...